Mitoxantron Sandoz (Mitoxantrone Hydrochloride)

Mitoxantrone intercalates into DNA and stabilizes the DNA‑topoisomerase II complex, preventing the enzyme from resealing DNA strands. This creates double‑strand breaks, halts DNA replication and transcription, and ultimately triggers programmed cell death in rapidly dividing cancer cells.

The dose of Mitoxantron Sandoz is individualized by the treating physician based on factors such as the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior treatment history. No fixed dosing regimen is provided in public literature.

Safety data for mitoxantrone in pregnancy are limited, and the drug is classified as contraindicated for use in pregnant or nursing women. It may cross the placenta and be excreted in breast milk, so avoidance is recommended.

To request Mitoxantron Sandoz, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mitoxantrone belongs to the anthracenedione class, offering a mechanism distinct from anthracyclines like doxorubicin. While both classes target topoisomerase II, mitoxantrone generally shows lower cumulative cardiotoxicity but carries a risk of secondary leukemia. Choice of agent depends on tumor type, prior therapy, and patient‑specific risk factors.

Mitoxantron Sandoz injection solution must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken vigorously to maintain stability.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional, typically over a period of several minutes to hours, depending on the prescribed protocol and patient tolerance.

The most serious adverse risks include cardiotoxicity leading to reduced heart function or heart failure, the development of secondary acute leukemia, and severe infections caused by profound neutropenia. Regular monitoring of cardiac function and blood counts is essential to mitigate these risks.

Mitoxantron Sandoz is contraindicated in patients with known hypersensitivity to mitoxantrone or any formulation component, those with uncontrolled cardiac disease, and pregnant or breastfeeding women. Caution is also advised for individuals with severe hepatic impairment or existing bone‑marrow failure.